Author - Ruslan Dorfman

medical cannabis

Cannabis – How can private health benefits plan sponsors and insurers make the right coverage decisions for plan members?

The legalization of cannabis poses a challenge for employers and insurers, as they are expected to cover the cost of medical cannabis as a part of their employee health benefits. A recent Deloitte report indicates that 7% of adult Canadian population are daily cannabis users, of which 29% are [...]

Read more...
DNA

August 2017 Pillcheck update to version GYIAUG212017

While our DNA does not change over time, clinical guidelines established by the scientific community are continuously refined and expanded to cover a growing number of medications. In order to provide a lifetime of Pillcheck value to our customers, we periodically update reports, incorporating the most up-to-date information and [...]

Read more...

Colon cancer treatment and genetic testing for DPYD deficiency

Patients diagnosed with advanced colon cancer have few treatment options besides surgery and aggressive chemotherapy. All chemotherapies are designed to block cell growth. Since all multiplying cells need to replicate their DNA, blocking DNA synthesis stops cell growth. The 5-Fluorouracil (5FU) drug is a modified nucleotide that blocks DNA [...]

Read more...

Your genetics determines the effectiveness of Tecta for you

What is Tecta? How does Tecta work? Tecta (pantoprazole) is prescribed to treat gastrointestinal ulcers, or for gastroesophageal reflux disease (GERD), which includes heartburn and acid reflux, and reflux esophagitis. Tecta is part of a family of drugs called Proton Pump Inhibitors (PPIs). These drugs block Proton Pumps, and reduces stomach [...]

Read more...